On the public citation graph
Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial
0 signed · 158 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1007/bf01641272openalex-snapshot
Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA
inferredcites →https://doi.org/10.1016/j.vaccine.2005.11.022openalex-snapshot
Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine
inferredcites →https://doi.org/10.1016/j.vaccine.2007.10.017openalex-snapshot
Clinical and immunologic responses to multiple doses of IMVAMUNE® (Modified Vaccinia Ankara) followed by Dryvax® challenge
inferredcites →https://doi.org/10.1016/j.vaccine.2009.05.095openalex-snapshot
Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain
inferredcites →https://doi.org/10.1016/j.vaccine.2009.11.030openalex-snapshot
A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE®
inferredcites →https://doi.org/10.1016/j.vaccine.2013.04.050openalex-snapshot
Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario
inferredcites →https://doi.org/10.1016/j.vaccine.2014.02.043openalex-snapshot
Phase II randomized, double-blinded comparison of a single high dose (5×108 TCID50) of modified vaccinia Ankara compared to a standard dose (1×108 TCID50) in healthy vaccinia-naïve individuals
inferredcites →https://doi.org/10.1016/j.vaccine.2014.08.022openalex-snapshot
Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis
inferredcites →https://doi.org/10.1016/s0147-9571(03)00025-0openalex-snapshot
Smallpox vaccination and bioterrorism with pox viruses
inferredcites →https://doi.org/10.1016/s0731-7085(99)00244-7openalex-snapshot
Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective
inferredcites →https://doi.org/10.1038/icb.1990.44openalex-snapshot
Vaccinia virus‐mediated damage of murine ovaries and protection by virus‐expressed interleukin‐2
inferredcites →https://doi.org/10.1038/sj.icb.7100118openalex-snapshot
Correlates of protective immunity in poxvirus infection: where does antibody stand?
inferredcites →https://doi.org/10.1056/nejm198011273032204openalex-snapshot
The Confirmation and Maintenance of Smallpox Eradication
inferredcites →https://doi.org/10.1086/376557openalex-snapshot
Development of a Novel Vaccinia‐Neutralization Assay Based on Reporter‐Gene Expression
inferredcites →https://doi.org/10.1093/infdis/122.4.303openalex-snapshot
Complications of Smallpox Vaccination, 1968: Results of Ten Statewide Surveys
inferredcites →https://doi.org/10.1093/infdis/jis753openalex-snapshot
Safety, Immunogenicity, and Surrogate Markers of Clinical Efficacy for Modified Vaccinia Ankara as a Smallpox Vaccine in HIV-Infected Subjects
inferredcites →https://doi.org/10.1093/infdis/jit105openalex-snapshot
Safety and Immunogenicity of Modified Vaccinia Ankara in Hematopoietic Stem Cell Transplant Recipients: A Randomized, Controlled Trial
inferredcites →https://doi.org/10.1097/ipc.0b013e31815c5e6eopenalex-snapshot
Routine Vaccination in HIV-Infected Adults
inferredcites →https://doi.org/10.1099/vir.0.010553-0openalex-snapshot
Evaluation of smallpox vaccines using variola neutralization
inferredcites →https://doi.org/10.1128/jvi.01797-08openalex-snapshot
Vaccinia Virus Extracellular Enveloped Virion Neutralization In Vitro and Protection In Vivo Depend on Complement
inferredcites →https://doi.org/10.1128/jvi.02061-06openalex-snapshot
Induction of Natural Killer Cell Responses by Ectromelia Virus Controls Infection
inferredcites →https://doi.org/10.1128/jvi.02152-12openalex-snapshot
Unusual Features of Vaccinia Virus Extracellular Virion Form Neutralization Resistance Revealed in Human Antibody Responses to the Smallpox Vaccine
inferredcites →https://doi.org/10.1371/journal.pone.0054407openalex-snapshot
Prospective Surveillance for Cardiac Adverse Events in Healthy Adults Receiving Modified Vaccinia Ankara Vaccines: A Systematic Review
inferredcites →https://doi.org/10.1371/journal.ppat.1000249openalex-snapshot
Surviving Mousepox Infection Requires the Complement System
inferredcites →https://doi.org/10.1542/peds.55.3.342openalex-snapshot
Smallpox Vaccination Reactions, Prophylaxis, and Therapy of Complications
inferredcites →https://doi.org/10.4049/jimmunol.171.10.4969openalex-snapshot
Cutting Edge: Long-Term B Cell Memory in Humans after Smallpox Vaccination
inferredcites →https://doi.org/10.4172/2157-2526.1000106openalex-snapshot
Likelihood of Smallpox Recurrence
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4107499openalex-extracted
A Randomized Phase 3 Trial to Assess the Immunogenicity and Safety of 3 Consecutively Produced Lots of Freeze-Dried MVA‑BN® Vaccine in Healthy Adults
inferred← citeshttps://doi.org/10.2139/ssrn.4572849openalex-extracted
Immunogenicity and Reactogenicity of Modified Vaccinia Ankara Pre-Exposure Vaccination Against Mpox According to Previous Smallpox Vaccine Exposure
inferred← citeshttps://doi.org/10.1001/jama.2022.18320openalex-snapshot
Human Monkeypox Virus Infection in the Immediate Period After Receiving Modified Vaccinia Ankara Vaccine
inferred← citeshttps://doi.org/10.1002/cpdd.1275openalex-snapshot
Anti‐Monkeypox Infection Approaches: From Prevention to Therapeutic Lines
inferred← citeshttps://doi.org/10.1002/jmv.29198openalex-snapshot
Epidemiological characteristics, clinical manifestations, and mental health status of human mpox cases: A multicenter cross‐sectional study in China
inferred← citeshttps://doi.org/10.1002/jmv.29407openalex-snapshot
Characterizing the acute antibody response of monkeypox and MVA‐BN vaccine following an Australian outbreak
inferred← citeshttps://doi.org/10.1002/mco2.70525openalex-snapshot
Monkeypox Virus: Epidemiology, Virology, Diagnosis, Vaccine, and Therapeutics
inferred← citeshttps://doi.org/10.1002/med.22085openalex-snapshot
An overview of the progress made in research into the Mpox virus
inferred← citeshttps://doi.org/10.1007/978-1-4939-6869-5_6openalex-snapshot
Generation and Production of Modified Vaccinia Virus Ankara (MVA) as a Vaccine Vector
inferred← citeshttps://doi.org/10.1007/978-3-031-57165-7_17openalex-snapshot
Poxvirus Vaccines: Past, Present, and Future
inferred← citeshttps://doi.org/10.1007/978-3-031-57165-7_7openalex-snapshot
Molecular Virology of Orthopoxviruses with Special Reference to Monkeypox Virus
inferred← citeshttps://doi.org/10.1007/s11904-023-00661-1openalex-snapshot
Mpox and HIV: a Narrative Review
inferred← citeshttps://doi.org/10.1007/s11904-023-00682-wopenalex-snapshot
Mpox and HIV—Collision of Two Diseases
inferred← citeshttps://doi.org/10.1007/s11904-025-00731-6openalex-snapshot
Update on Vaccination Recommendations for Adults with HIV
inferred← citeshttps://doi.org/10.1007/s12026-018-8991-xopenalex-snapshot
Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice
inferred← citeshttps://doi.org/10.1007/s40121-017-0165-yopenalex-snapshot
Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part II
inferred← citeshttps://doi.org/10.1007/s40506-022-00260-5openalex-snapshot
Mpox: Special Considerations in the Immunocompromised Host
inferred← citeshttps://doi.org/10.1016/bs.aivir.2016.07.001openalex-snapshot
Modified Vaccinia Virus Ankara
inferred← citeshttps://doi.org/10.1016/j.biologicals.2026.101886openalex-snapshot
Alternative approaches to phase III clinical trials for vaccine efficacy and licensure: the role of real-world evidence – a meeting report
inferred← citeshttps://doi.org/10.1016/j.ebiom.2022.104424openalex-snapshot
The land-scape of immune response to monkeypox virus
inferred← citeshttps://doi.org/10.1016/j.eclinm.2023.102420openalex-snapshot
Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study
inferred← citeshttps://doi.org/10.1016/j.idnow.2022.09.013openalex-snapshot
Proposal of the French HIV Society on the CD4 threshold below which patients living with HIV who wish to be vaccinated against Monkeypox should receive a 3-dose regimen
inferred← citeshttps://doi.org/10.1016/j.jfma.2023.10.019openalex-snapshot
Update on the M-pox virus and safety measures taken against it globally
inferred← citeshttps://doi.org/10.1016/j.jinf.2023.01.005openalex-snapshot
Facial nerve palsy as a possible adverse drug reaction of the modified vaccinia ankara-bavarian nordic (MVA-BN) smallpox vaccine: A pharmacovigilance analysis
inferred← citeshttps://doi.org/10.1016/j.jinf.2025.106602openalex-snapshot
Humoral and T-cell responses following MVA-BN booster vaccination against mpox virus clades Ib and IIb
inferred← citeshttps://doi.org/10.1016/j.micpath.2023.106027openalex-snapshot
Monkeypox virus: A review
inferred← citeshttps://doi.org/10.1016/j.nmni.2023.101084openalex-snapshot
Monkeypox breakthrough infections and side-effects: Clarion call for nex-gen novel vaccine
inferred← citeshttps://doi.org/10.1016/j.vaccine.2017.02.032openalex-snapshot
Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial
inferred← citeshttps://doi.org/10.1016/j.vaccine.2019.10.049openalex-snapshot
Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge
inferred← citeshttps://doi.org/10.1016/j.vaccine.2020.01.055openalex-snapshot
Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trial
inferred← citeshttps://doi.org/10.1016/j.vaccine.2020.01.058openalex-snapshot
A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS
inferred← citeshttps://doi.org/10.1016/j.vaccine.2020.08.050openalex-snapshot
The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform
inferred← citeshttps://doi.org/10.1016/j.vaccine.2022.10.056openalex-snapshot
A randomized phase 3 trial to assess the immunogenicity and safety of 3 consecutively produced lots of freeze-dried MVA-BN® vaccine in healthy adults
inferred← citeshttps://doi.org/10.1016/j.vaccine.2024.05.035openalex-snapshot
Effectiveness of JYNNEOS vaccine against symptomatic mpox disease in adult men in Los Angeles County, August 29, 2022 to January 1, 2023
inferred← citeshttps://doi.org/10.1016/j.vaccine.2025.127889openalex-snapshot
The LVD/NIAID/NIH MVA1974 clone as an Mpox vaccine – preclinical assessment upon in a model of lethal infection with Orthopoxvirus monkeypox in mice
inferred← citeshttps://doi.org/10.1016/j.ymthe.2017.06.017openalex-snapshot
Production of a Chikungunya Vaccine Using a CHO Cell and Attenuated Viral-Based Platform Technology
inferred← citeshttps://doi.org/10.1016/s1473-3099(23)00546-7openalex-snapshot
Mpox breakthrough infections: concerns and actions
inferred← citeshttps://doi.org/10.1016/s1773-035x(24)00300-9openalex-snapshot
Vaccination contre le Mpox : état des lieux et perspectives
inferred← citeshttps://doi.org/10.1038/s41392-022-01215-4openalex-snapshot
Monkeypox: epidemiology, pathogenesis, treatment and prevention
inferred← citeshttps://doi.org/10.1038/s41467-018-03662-6openalex-snapshot
A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses
inferred← citeshttps://doi.org/10.1038/s41467-024-48180-wopenalex-snapshot
Predicting vaccine effectiveness for mpox
inferred← citeshttps://doi.org/10.1038/s41541-020-00240-0openalex-snapshot
Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans
inferred← citeshttps://doi.org/10.1038/s41598-018-24820-2openalex-snapshot
Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines
inferred← citeshttps://doi.org/10.1056/nejmc2306239openalex-snapshot
Antibody Titers against Mpox Virus after Vaccination
inferred← citeshttps://doi.org/10.1056/nejmoa1817307openalex-snapshot
Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox
inferred← citeshttps://doi.org/10.1056/nejmoa2215201openalex-snapshot
Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States
inferred← citeshttps://doi.org/10.1073/pnas.2202069119openalex-snapshot
Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection
inferred← citeshttps://doi.org/10.1080/14760584.2016.1175305openalex-snapshot
Defending against smallpox: a focus on vaccines
inferred← citeshttps://doi.org/10.1080/14760584.2018.1526085openalex-snapshot
A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection
inferred← citeshttps://doi.org/10.1080/14760584.2024.2397006openalex-snapshot
Vaccines against mpox: MVA-BN and LC16m8
inferred← citeshttps://doi.org/10.1080/14760584.2025.2589213openalex-snapshot
Safety of live attenuated vaccines in immunocompromised individuals and pregnant women: a systematic literature review
inferred← citeshttps://doi.org/10.1080/14760584.2026.2689611openalex-snapshot
Recent advances for the pharmaceutical production of highly attenuated poxviruses as viral vector platforms
inferred← citeshttps://doi.org/10.1080/21645515.2024.2384189openalex-snapshot
Equivalence of freeze-dried and liquid-frozen formulations of MVA-BN as smallpox and mpox vaccine
inferred← citeshttps://doi.org/10.1089/aid.2023.0034openalex-snapshot
Human Mpox in People Living with HIV: Epidemiologic and Clinical Perspectives from Nigeria
inferred← citeshttps://doi.org/10.1093/infdis/jiac455openalex-snapshot
One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines
inferred← citeshttps://doi.org/10.1093/infdis/jiae138openalex-snapshot
Mpox-Specific Immune Responses Elicited by Vaccination or Infection in People With HIV
inferred← citeshttps://doi.org/10.1093/infdis/jiy326openalex-snapshot
Effects of Treatment Delay on Efficacy of Tecovirimat Following Lethal Aerosol Monkeypox Virus Challenge in Cynomolgus Macaques
inferred← citeshttps://doi.org/10.1093/ofid/ofaf536openalex-snapshot
Antibody Responses are Sustained 2 Years Post-Mpox Infection but not Following Modified Vaccinia Ankara–Bavarian Nordic Vaccination
inferred← citeshttps://doi.org/10.1097/coh.0000000000001009openalex-snapshot
Insights into host responses, viral evolution, and implications for vaccines and therapeutics for Mpox
inferred← citeshttps://doi.org/10.1097/jnc.0000000000000365openalex-snapshot
Monkeypox Virus Outbreak 2022: Key Epidemiologic, Clinical, Diagnostic, and Prevention Considerations
inferred← citeshttps://doi.org/10.1097/olq.0000000000001974openalex-snapshot
Breakthrough Mpox Outbreak Investigation, the Delicate Balance Between Host Immune Response and Viral Immune Escape
inferred← citeshttps://doi.org/10.1097/qad.0000000000003733openalex-snapshot
Viral blips and virologic failures following mpox vaccination with MVA-BN among people with HIV
inferred← citeshttps://doi.org/10.1097/qco.0000000000000994openalex-snapshot
Mpox in people living with HIV
inferred← citeshttps://doi.org/10.1098/rstb.2016.0295openalex-snapshot
A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?
inferred← citeshttps://doi.org/10.1101/2022.09.07.22279689openalex-snapshot
Single and 2-dose vaccinations with MVA-BN ® induce durable B cell memory responses in healthy volunteers that are comparable to older generation replicating smallpox vaccines
inferred← citeshttps://doi.org/10.1101/2022.09.25.509429openalex-snapshot
Innate–adaptive IFN cross-talk reprograms myeloid and T cells for antitumor immunity with a second-generation recombinant MVA
inferred← citeshttps://doi.org/10.1101/2024.06.06.24308551openalex-snapshot
Safety and Effectiveness of LC16m8 for Pre-Exposure Prophylaxis against mpox in a High-Risk Population: An Open-Label Randomized Trial
inferred← citeshttps://doi.org/10.1111/hiv.13661openalex-snapshot
Mpox in people with HIV : A narrative review
inferred← citeshttps://doi.org/10.1111/tid.14051openalex-snapshot
Cowpox to COVID: History of vaccination in the immunocompromised host
inferred← citeshttps://doi.org/10.1128/jvi.01154-19openalex-snapshot
Modified Vaccinia Virus Ankara Can Induce Optimal CD8 + T Cell Responses to Directly Primed Antigens Depending on Vaccine Design
inferred← citeshttps://doi.org/10.1128/jvi.01843-25openalex-snapshot
Protective efficacy of a genetically modified attenuated vaccinia virus Tiantan strain against monkeypox virus challenge in a small animal model
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-19-0183openalex-snapshot
A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules
inferred← citeshttps://doi.org/10.1172/jci167632openalex-snapshot
Vaxxing to elimination: smallpox vaccines as tools to fight mpox
inferred← citeshttps://doi.org/10.1177/09564624251349888openalex-snapshot
Exploring mpox vaccination uptake and tolerability among people living with HIV: A study in an infectious disease unit in Italy
inferred← citeshttps://doi.org/10.1186/s12889-024-19260-9openalex-snapshot
Willingness to receive mpox vaccine among men who have sex with men: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1186/s12916-023-02872-0openalex-snapshot
Unexpectedly higher levels of anti-orthopoxvirus neutralizing antibodies are observed among gay men than general adult population
inferred← citeshttps://doi.org/10.1371/journal.pone.0138348openalex-snapshot
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis
inferred← citeshttps://doi.org/10.1371/journal.pone.0149364openalex-snapshot
Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines
inferred← citeshttps://doi.org/10.1371/journal.pone.0157335openalex-snapshot
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects
inferred← citeshttps://doi.org/10.1371/journal.pone.0195897openalex-snapshot
Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial
inferred← citeshttps://doi.org/10.14218/jerp.2021.00004openalex-snapshot
Research, Development and Application of COVID-19 Vaccines: Progress, Challenges, and Prospects
inferred← citeshttps://doi.org/10.15212/zoonoses-2024-0044openalex-snapshot
Strategies for the Modification of Vaccinia Virus towards a Better Vaccine Vector
inferred← citeshttps://doi.org/10.15585/mmwr.mm7132e4openalex-snapshot
Interim Guidance for Prevention and Treatment of Monkeypox in Persons with HIV Infection — United States, August 2022
inferred← citeshttps://doi.org/10.1586/14760584.2016.1106319openalex-snapshot
Recombinant modified vaccinia virus Ankara-based malaria vaccines
inferred← citeshttps://doi.org/10.18433/jpps33138openalex-snapshot
Monkeypox: Virology, Pathophysiology, Clinical Characteristics, Epidemiology, Vaccines, Diagnosis, and Treatments
inferred← citeshttps://doi.org/10.21055/0370-1069-2023-4-24-31openalex-snapshot
Comparison of the Efficacy of Different Schemes for Using Recombinant Vector Vaccines against Ebola Fever, Based on Vaccinia Virus, MVA Strain
inferred← citeshttps://doi.org/10.21055/0370-1069-2025-4-6-16openalex-snapshot
Analysis of the Experience of Improving the Safety of Anti-Smallpox Vaccines
inferred← citeshttps://doi.org/10.2139/ssrn.4939172openalex-snapshot
Plaque Reduction Neutralization Test for Smallpox Vaccines: Laboratory Optimization and Validation Method for Immunogenicity Assessment
inferred← citeshttps://doi.org/10.30895/2221-996x-2023-23-1-26-41openalex-snapshot
Safety and immunogenicity of IMVAMUNE®, a third-generation vaccine based on the modified vaccinia Ankara (MVA) strain
inferred← citeshttps://doi.org/10.32388/gdwpcvopenalex-snapshot
A Historical to Future Perspective of Monkeypox Virus and Future Immunotherapeutics
inferred← citeshttps://doi.org/10.3389/fimmu.2018.01756openalex-snapshot
Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model
inferred← citeshttps://doi.org/10.3389/fimmu.2023.1182963openalex-snapshot
A recombinant Modified Vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infection
inferred← citeshttps://doi.org/10.3389/fmicb.2023.1094794openalex-snapshot
Monkeypox: a global health emergency
inferred← citeshttps://doi.org/10.3390/ijerph20042963openalex-snapshot
Safety and Efficacy of Post-Eradication Smallpox Vaccine as an Mpox Vaccine: A Systematic Review with Meta-Analysis
inferred← citeshttps://doi.org/10.3390/pathogens11080924openalex-snapshot
Monkeypox and Its Possible Sexual Transmission: Where Are We Now with Its Evidence?
inferred← citeshttps://doi.org/10.3390/pathogens8030133openalex-snapshot
A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge
inferred← citeshttps://doi.org/10.3390/pathogens9121001openalex-snapshot
NF-κB as an Important Factor in Optimizing Poxvirus-Based Vaccines against Viral Infections
inferred← citeshttps://doi.org/10.3390/v15010103openalex-snapshot
Smallpox, Monkeypox and Other Human Orthopoxvirus Infections
inferred← citeshttps://doi.org/10.3390/v15091844openalex-snapshot
Immunogenicity and Efficacy of Vaccination in People Living with Human Immunodeficiency Virus
inferred← citeshttps://doi.org/10.3390/v17121526openalex-snapshot
Mpox: Exploring Epidemiology, Disease Outcomes, and Preventative Vaccination Among People with HIV During the Ongoing Outbreaks
inferred← citeshttps://doi.org/10.3390/v17121558openalex-snapshot
Mpox in People Living with HIV: Clinical Challenges, Preventive Strategies and Public Health Implications
inferred← citeshttps://doi.org/10.3390/v9090242openalex-snapshot
Are We Prepared in Case of a Possible Smallpox-Like Disease Emergence?
inferred← citeshttps://doi.org/10.3390/v9110318openalex-snapshot
Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
inferred← citeshttps://doi.org/10.3390/vaccines10040533openalex-snapshot
Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein
inferred← citeshttps://doi.org/10.3390/vaccines10091419openalex-snapshot
Preventing the Next Pandemic: Is Live Vaccine Efficacious against Monkeypox, or Is There a Need for Killed Virus and mRNA Vaccines?
inferred← citeshttps://doi.org/10.3390/vaccines10091516openalex-snapshot
Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
inferred← citeshttps://doi.org/10.3390/vaccines10122151openalex-snapshot
Psychological Antecedents of Healthcare Workers towards Monkeypox Vaccination in Nigeria
inferred← citeshttps://doi.org/10.3390/vaccines11030528openalex-snapshot
Perception of and Vaccine Readiness towards Mpox among Men Who Have Sex with Men Living with HIV in China: A Cross-Sectional Study
inferred← citeshttps://doi.org/10.3390/vaccines11061093openalex-snapshot
The Global Monkeypox (Mpox) Outbreak: A Comprehensive Review
inferred← citeshttps://doi.org/10.3390/vaccines11091410openalex-snapshot
Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine—A Systematic Review and Meta-Analysis of Randomized Controlled Trials
inferred← citeshttps://doi.org/10.3390/vaccines12040385openalex-snapshot
A Quadrivalent mRNA Immunization Elicits Potent Immune Responses against Multiple Orthopoxviral Antigens and Neutralization of Monkeypox Virus in Rodent Models
inferred← citeshttps://doi.org/10.3390/vaccines13090930openalex-snapshot
Immune Response to MVA-BN Vaccination for Mpox: Current Evidence and Future Directions
inferred← citeshttps://doi.org/10.3390/vaccines14010040openalex-snapshot
Challenges in the Vaccination of HIV-Infected Individuals
inferred← citeshttps://doi.org/10.3390/vaccines6010008openalex-snapshot
Challenges and Achievements in Prevention and Treatment of Smallpox
inferred← citeshttps://doi.org/10.3390/vaccines6020029openalex-snapshot
Clinical Advances in Viral-Vectored Influenza Vaccines
inferred← citeshttps://doi.org/10.3390/vaccines8010069openalex-snapshot
Plasmablast, Memory B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified Vaccinia Ankara Vaccine
inferred← citeshttps://doi.org/10.3390/vaccines8030396openalex-snapshot
IMVAMUNE® and ACAM2000® Provide Different Protection against Disease When Administered Postexposure in an Intranasal Monkeypox Challenge Prairie Dog Model
inferred← citeshttps://doi.org/10.36233/0507-4088-2019-64-5-206-214openalex-snapshot
We should be prepared to smallpox re-emergence
inferred← citeshttps://doi.org/10.4067/s0716-10182024000200259openalex-snapshot
Orientaciones para el manejo ambulatorio de adultos que viven con VIH en Chile
inferred← citeshttps://doi.org/10.47836/mjmhs.19.s9.41openalex-snapshot
Vaccines for Orthopoxviruses: A Review
inferred← citeshttps://doi.org/10.6084/m9.figshare.26589780openalex-snapshot
Additional file 1 of Unexpectedly higher levels of anti-orthopoxvirus neutralizing antibodies are observed among gay men than general adult population
inferred← citeshttps://doi.org/10.6084/m9.figshare.26749235openalex-snapshot
Additional file 1 of Willingness to receive mpox vaccine among men who have sex with men: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.6084/m9.figshare.26749238openalex-snapshot
Additional file 2 of Willingness to receive mpox vaccine among men who have sex with men: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.6084/m9.figshare.26749241openalex-snapshot
Additional file 3 of Willingness to receive mpox vaccine among men who have sex with men: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.70675/d9e1edb5z9baaz4166z8cbcz7ded11e4c2d6openalex-snapshot
Développement d’un vaccin thérapeutique multi-antigénique contre la tuberculose et étude de l’influence des antibiotiques antituberculeux sur son immunogénicité
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.